

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims.

1. (original) A method for treating inflammation comprising administering to a patient in need thereof a therapeutically effective amount of KGF-2Δ28.
- 2-5. (cancelled)
6. (new) A method for treating inflammation comprising administering to a patient in need thereof a therapeutically effective amount of a polypeptide comprising amino acids 69 to 208 of SEQ ID NO:2.
7. (new) The method of claim 6, wherein said inflammation is associated with a chronic or acute disease.
8. (new) The method of claim 7, wherein said disease is selected from the group consisting of psoriasis, eczema, dermatitis, and arthritis.
9. (new) The method of claim 6, wherein said inflammation is associated with an inflammatory condition.
10. (new) The method of claim 9, wherein said condition is selected from the group consisting of inflammation associated with infection, ischemia-reperfusion injury, endotoxin lethality, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, and inflammation resulting from overproduction of cytokines.
11. (new) The method of claim 6, wherein said polypeptide is administered prior to the onset of said inflammation.
12. (new) The method of claim 6, wherein said polypeptide is administered after the onset of said inflammation.

13. (new) The method of claim 6, wherein said polypeptide comprises amino acids 63 to 208 of SEQ ID NO:2.

14. (new) The method of claim 13, wherein said inflammation is associated with a chronic or acute disease.

15. (new) The method of claim 14, wherein said disease is selected from the group consisting of psoriasis, eczema, dermatitis, and arthritis.

16. (new) The method of claim 13, wherein said inflammation is associated with an inflammatory condition.

17. (new) The method of claim 16, wherein said condition is selected from the group consisting of inflammation associated with infection, ischemia-reperfusion injury, endotoxin lethality, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, and inflammation resulting from overproduction of cytokines.

18. (new) The method of claim 13, wherein said polypeptide is administered prior to the onset of said inflammation.

19. (new) The method of claim 13, wherein said polypeptide is administered after the onset of said inflammation.